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http://dx.doi.org/10.1016/j.ccr.2013.01.023SUMMARYOncogenic Kras activates a plethora of signaling pathways, but our understanding of critical Ras effectors is
still very limited. We show that cell-autonomous phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-
dependent protein kinase 1 (PDK1), but not Craf, are key effectors of oncogenic Kras in the pancreas, medi-
ating cell plasticity, acinar-to-ductal metaplasia (ADM), and pancreatic ductal adenocarcinoma (PDAC)
formation. This contrasts with Kras-driven non-small cell lung cancer, where signaling via Craf, but not
PDK1, is an essential tumor-initiating event. These in vivo genetic studies together with pharmacologic treat-
ment studies in models of human ADM and PDAC demonstrate tissue-specific differences of oncogenic Kras
signaling and define PI3K/PDK1 as a suitable target for therapeutic intervention specifically in PDAC.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is nearly uniformly
fatal despite maximal treatment, with fewer than 1% of patients
surviving 5 years (Carpelan-Holmstro¨m et al., 2005). A wealth of
molecular studies have identified mutant Kras as the initiating
event (Hidalgo, 2010; Hingorani et al., 2003; Morris et al., 2010;
Pylayeva-Gupta et al., 2011). Expression of KrasG12D or KrasG12V
in the murine pancreas induces acinar cell dedifferentiation,
acinar-to-ductal metaplasia (ADM), and premalignant precursor
lesions, called pancreatic intraepithelial neoplasia (PanIN) thatSignificance
Kras-driven tumors such as PDAC, NSCLC, or colon cance
However, the underlyingmolecular mechanisms are largely unk
but the functional relevance of specific Kras effectors is unclea
gable, this has hampered progress toward targeted therape
context-specific effector pathways of oncogenic Kras in PDA
PDK1 signaling as a critical and therapeutically tractable axis
406 Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc.progress to metastatic PDAC (Guerra et al., 2007; Hingorani
et al., 2003; Morris et al., 2010; Pinho et al., 2011; Seidler et al.,
2008).Oncogenic Kras activates a plethora of signalingpathways,
including canonical Raf/MEK/ERK, PI3K/AKT, RalGDS/p38
MAPK, Rac and Rho, Rassf1, NF1, p120GAP, and PLC-ε (Castel-
lanoandDownward, 2011;Pylayeva-Guptaetal., 2011).However,
which of these effector pathways of oncogenic Kras control cell
fate decisions and PDAC formation remains an outstanding
question (Morris et al., 2010; Pylayeva-Gupta et al., 2011).
The PI3K/AKT pathway is uniformly activated in human
PDAC and mouse models of Kras-driven pancreatic cancerr differ in prognosis and response to targeted therapies.
nown. Oncogenic Kras activates diverse signaling pathways
r for most cancer types. Because Kras is considered undrug-
utic interventions. We provide in vivo genetic evidence for
C and NSCLC and define cell autonomous Kras/ PI3K/
in pancreatic cancer initiation and maintenance.
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PI3Ks are a family of heterodimeric lipid kinases composed of
catalytic and regulatory subunits that, on stimulation, catalyze
production of the second messenger phosphatidylinositol-
3,4,5-triphosphate (PIP3), which activates downstream kinases,
such as PDK1 and AKT (Castellano and Downward, 2011; Bader
et al., 2005). p110a, which is encoded by PIK3CA, is the catalytic
subunit of the ubiquitously expressed class IA PI3Ka. Hotspot
mutations of p110a that activate PI3K signaling have been
identified in the helical domain (E542K and E545K) and the cata-
lytic domain (H1047R) in a variety of human cancers, including
breast and lung (Bader et al., 2005; Liu et al., 2009). Transgenic
expression of p110aH1047R in mice induces breast and lung
cancer (Adams et al., 2011; Engelman et al., 2008; Liu et al.,
2011).
Taking advantage of genetically engineered murine and
patient-derived humanized cancer models, we set out to analyze
the contribution of Kras effector pathways to PDAC and NSCLC
development.
RESULTS
Pancreas-Specific PI3K Pathway Activation by
Expression of Oncogenic p110aH1047R Induces ADM
and Premalignant PanIN
To explore the role of the PI3K/AKT signaling pathway in Kras-
induced cell plasticity, ADM, and PDAC formation, we generated
a latent oncogenic PIK3CAH1047R (encoding p110aH1047R)
allele silenced by a lox-stop-lox (LSL) cassette as a knock-in
at the mouse Rosa26 locus (LSL-PIK3CAH1047R mouse line;
Figures S1A–S1C available online). To activate the expression
of p110aH1047R and thus PI3K signaling, specifically in the
pancreas, we used the well-established Ptf1aCre driver line to
direct recombination in pancreatic acini, ducts, and islets
(Figures S1D and S1E) (Nakhai et al., 2007; Seidler et al., 2008;
von Werder et al., 2012).
Transgenic expression of p110aH1047R from the Rosa26 locus
resulted in moderately increased PIP3 levels in the pancreas,
similar to expression of KrasG12D from the endogenous Kras
locus in the established KrasG12D knock-in mouse model (Fig-
ures 1A and 1B). Importantly, we observed no obvious difference
in the p110a protein levels in pancreatic tissue lysates between
Ptf1aCre/+;LSL-PIK3CAH1047R/+ animals and Ptf1aCre/+;LSL-
KrasG12D knock-in mice (Figure 1B), even though Ptf1aCre/+;
LSL-PIK3CAH1047R/+ animals carried PIK3CAH1047R in the
Rosa26 locus in addition to their endogenous Pik3ca. Ptf1aCre/+;
LSL-PIK3CAH1047R/+ mice were viable and revealed no overt
phenotype after birth. However, pancreatic size and weight
were increased, as previously shown in the KrasG12D model
(Figure 1C).
Histopathologic analyses revealed that all Ptf1aCre/+;LSL-
PIK3CAH1047R/+ mice developed massive induction of ADM,
a condition where terminally differentiated acinar cells dediffer-
entiate into a progenitor-like state and acquire features of ductal
cells (Figure 1D) (Pinho et al., 2011). Furthermore, all animals
developed PanIN, a precursor lesion of PDAC (Figure 1D)
(Hruban et al., 2006). The amount and grade of these lesions
increased over time from PanIN-1A, already present in
1-month-old mice, to PanIN-3, found in some 9-month-oldanimals, which represents carcinoma in situ (Figures 1D and
1E). The PIK3CAH1047R/+ and KrasG12D/+ models showed very
similar patterns of ADM induction and PanIN progression
(Figures 1D and 1E) and markers of PI3K pathway activation
were almost identical, as shown by immunohistochemistry and
western blot analysis of tissue lysates (Figures 1F and 1G). Indi-
cators of PI3K signaling, such as proliferation of PanIN lesions,
were consistently similar in both models (Figures S1F and
S1G). These observations support the view that pancreas-
specific activation of PI3K signaling phenocopies KrasG12D-
induced cellular plasticity and PanIN formation.
To confirm that acinar cell plasticity via ADM is indeed involved
in PanIN and PDAC development, we used an elastase-1 Cre
driver line (Stanger et al., 2005) to specifically activate
p110aH1047R in acinar cells. This induced ADMand PanIN lesions
with the same frequency as expression of oncogenic KrasG12D
(Figures S1H–S1J). In contrast, pancreas-specific constitutive
activation of Rac1 signaling by expressing a dominant active
Rac1G12V allele from the Rosa26 locus (Ptf1aCre/+;LSL-
Rac1G12V/+ mice) (Srinivasan et al., 2009) failed to induce ADM
and PanINs (Figure S1K). Since Rac1 is a downstream effector
of PI3K and is activated in the KrasG12D model of pancreatic
cancer (Heid et al., 2011), failure of Rac1G12V to induce ADM
and PanINs argues for the specific involvement of canonical
PI3K/AKT signaling in pancreatic tumor formation.
Expression of Oncogenic p110aH1047R in the Pancreas
Phenocopies KrasG12D-Induced Metastatic PDAC
To test whether p110aH1047R is also capable of inducing
pancreatic cancer, we aged Ptf1aCre/+;LSL-PIK3CAH1047R/+
mice. All animals in the tumor watch cohort developed PDAC
within 800 days (Figures 2A, 2B, and S2A). Comparison of
tumor formation and survival of PIK3CAH1047R and KrasG12D
mutant animals revealed striking similarities, with nearly iden-
tical survival times and similar rates of metastasis (Figures
2A and S2B). p110aH1047R-induced tumors were histopatho-
logically indistinguishable from human and murine KrasG12D-
induced PDAC and showed the full spectrum of the human
disease, ranging from well-differentiated ductal PDAC to undif-
ferentiated tumors and typical metastasis to lymph nodes,
liver, and lung (Figures 2B, S2A, and S2B) (Hruban et al.,
2006).
To explore activation of PI3K signaling in p110aH1047R- and
KrasG12D-driven pancreatic cancer, we analyzed tissues from
these animals using phospho-specific antibodies. Similar acti-
vation of the key downstream effectors of PI3K signaling,
pAKT-T308, pAKT-S473, and pGSK3b-S9 was observed in
both models (Figures 2C and 2D). Importantly, we found that
mutant p110aH1047R did not activate Ras in primary tissue
specimens and PDAC cell lines from Ptf1aCre/+;PIK3CAH1047R/+
animals, indicating that the effects observed in the PIK3-
CAH1047R model were not due to Ras cross activation (Figures
S2C and S2D). Consistent with data from pancreatic tissues
of the Ptf1aCre/+;LSL-PIK3CAH1047R/+ model (Figure 1B), we
found no obvious increase of p110a expression levels in PIK3-
CAH1047R mutant PDAC cell lines (Figure S2D). This accords
with previous findings that p110a not bound to the p85 regula-
tory subunit is unstable and rapidly degraded (Engelman et al.,
2008).Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc. 407
Figure 1. Constitutive Activation of PI3K Signaling Causes ADM and Neoplastic Changes in the Pancreas
(A) Genetic strategy used to activate p110aH1047R or KrasG12D expression in the pancreas.
(B) Immunoblot analysis of p110a expression levels (upper panel) and PIP3 activity (lower panel) in pancreata of 6-week-old control (Ctrl), Ptf1aCre/+;LSL-
KrasG12D/+ (KrasG12D/+) and Ptf1aCre/+;LSL-PIK3CAH1047R/+ (PIK3CAH1047R/+) compound mutant mice (n = 3 per genotype).
(legend continued on next page)
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Figure 2. Expression of Oncogenic p110aH1047R Induces Metastatic PDAC
(A) Kaplan-Meier survival curves of the indicated genotypes (n.s., not significant; ***p < 0.001, log-rank test).
(B) Macroscopic and microscopic images of PDAC and associated metastasis indicated by arrows in PIK3CAH1047R/+ mutant mice.
(C) Immunohistochemical analysis of PI3K/AKT pathway activation in p110aH1047R (upper panel) and KrasG12D (lower panel) induced PDAC.
(D) Immunoblot analysis of PI3K/AKT pathway activation in the pancreas of 9-month-old Ctrl and age-matched PanIN-bearing pancreata and PDAC from
PIK3CAH1047R/+ and KrasG12D/+mutant mice. b-actin was used as loading control. Insets show representative lesions in high magnification. Scale bars, 50 mm for
micrographs, 20 mm for insets.
See also Figure S2.
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Program in the Pancreas that Is Bypassed by Loss of
Cdkn2a
We next analyzed tumor-suppressive mechanisms in the
PIK3CAH1047R model. Expression of p110aH1047R-induced a
senescence program in the pancreas. All low-grade PanIN
lesions examined stained positive for senescence-associated
b-galactosidase (SA-b-Gal), which has been recently shown
to be the only reliable oncogene-induced senescence bio-
marker in the pancreas (Figure S2E) (Caldwell et al., 2012).
Importantly, these lesions showed concomitant upregulation
of both Cdkn2a gene products, p16/Ink4a and p19/Arf,
and activation of the p53/p21Cip1 pathway (Figures S2E
and S2F).(C) Representative images and weight of KrasG12D/+ and PIK3CAH1047R/+ mutant
(D) Representative alcian blue and hematoxylin and eosin (H&E) stained sections
Ptf1aCre/+;PIK3CAH1047R/+ (upper panel) and Ptf1aCre/+;LSL-KrasG12D/+ (lower pa
6 months, 9 months, 9 months). The arrow indicates a PanIN-1 and the arrowhe
Scale bars, 50 mm.
(E) Quantification of ADM and PanIN progression in the KrasG12D/+ and PIK3CAH
(F) Immunohistochemical analysis of PI3K/AKT pathway activation in ADMs and P
mutant mice. Insets show representative lesions in high magnification. Scale bar
(G) Immunoblot analysis of PI3K/AKTpathway activation in control (Ctrl),PIK3CAH
as loading control. Error bars, ± SEM.
See also Figure S1.In PDAC however, p16/Ink4a and p19/Arf expression is lost as
demonstrated previously in the KrasG12D model (Figure S2F and
data not shown) (Bardeesy et al., 2006). Consistent with this,
genomic analyses revealed frequent deletion of the Cdkn2a
locus in p110aH1047R-induced cancers (data not shown). Again,
these observations demonstrate that the PIK3CAH1047R model
phenocopies KrasG12D-induced PDAC with respect to tumor
suppressor usage (Bardeesy et al., 2006). Accordingly, mim-
icking loss of heterozygosity of Cdkn2a by inactivation of one
allele using floxed Cdkn2a mice (Bardeesy et al., 2006) acceler-
ated PDAC formation in the PIK3CAH1047R and KrasG12D model
(Figures S2G and S2H). To investigate the effect ofCdkn2a inac-
tivation on oncogene-induced senescence of PanIN lesions, we
inactivated both Cdkn2a alleles. As expected, this completelypancreata.
of ADM and different grades of pancreatic intraepithelial neoplasia (PanIN) in
nel) mutant animals (age from left to right, respectively: 1 month, 3 months,
ad a PanIN-2 lesion. Insets show representative lesions in high magnification.
1047R/+ models (n = 3 per time point; 3 representative slides per mouse).
anINs of 6-month-old Ptf1aCre/+;PIK3CAH1047R/+ and Ptf1aCre/+;LSL-KrasG12D/+
s, 50 mm for micrographs, 20 mm for insets.
1047R/+ andKrasG12D/+mutant pancreata of 6-month-oldmice. b-actin was used
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Figure 3. PI3K/AKT Pathway Activation in
Human Pancreatic ADM and Neoplasia
(A) H&E stains and immunohistochemical analysis
of CK19 and PI3K/AKT pathway activation in
human ADM.
(B) H&E staining and immunohistochemical PI3K/
AKT pathway analysis of human low- and high-
grade PanINs and PDAC.
(C) Frequency of PI3K pathway activation in ADM,
PanINs and PDAC. Bar graphs show the
percentage of lesions that stained positive or
negative on human tissue microarrays for pAKT-
T308. ADM (n = 21 patients), PanINs (n = 32
patients), and PDAC (n = 205 patients).
(D) Immunoblot analysis of PI3K/AKT pathway
activation in protein lysates of normal human
pancreatic cells (panc.), patient-derived low
passaged primary PDAC cells (n = 3 patients), and
primary patient-derived PDAC xenografts (n = 7
patients). b-actin was used as loading control.
Insets show representative lesions in high magni-
fication. Scale bars, 50 mm for micrographs, 20 mm
for insets.
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S2J). These findings demonstrate the importance of the Cdkn2a
tumor suppressor locus for PDAC progression. Interestingly,
median survival times were indistinguishable between both
heterozygous deletion models, arguing that identical pathways
and tumor suppressors operate in p110aH1047R- and KrasG12D-
driven PDAC formation.
Taken together, these murine in vivo modeling studies clearly
demonstrate that PI3K signaling induces acinar cell plasticity,
ADM, PanIN formation, senescence via upregulation of p16/
Ink4a and p19/Arf, bypass of senescence by inactivation of
Cdkn2a, and ultimately PDAC formation.
PI3K Pathway Activation in Human ADM, PanIN,
and PDAC
PI3K/AKT activation is a classical and uniform feature of human
PDAC (Jimeno et al., 2008; Kennedy et al., 2011; Reichert et al.,
2007; Ying et al., 2011). However, the role of PI3K/AKT signaling410 Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc.during the early stages of human pancre-
atic carcinogenesis, namely ADM and
PanIN formation, remains unclear. To
test our hypothesis that the PI3K/AKT
pathway is activated in human ADM,
PanIN and PDAC, we analyzed key surro-
gates of PI3K signaling: AKT-T308/S473
and GSK3b-S9 phosphorylation (Figures
3A and 3B). In accordance with the
murine in vivo studies, we observed
strong activation of PI3K signaling in
tissue microarrays of nearly all human
ADM (n = 21), PanIN (n = 32), and PDAC
(n = 205) specimens (Figure 3C).
In addition, we validated PI3K pathway
activation in human PDAC using patient-
derived primary xenografted tumors,
early-passage cell lines, and normalpancreatic tissue (Figure 3D). These data suggest that PI3K/
AKT signaling is activated at the earliest stages of tumor evolu-
tion in humans and controls pancreatic cell plasticity and
carcinogenesis.
Elimination of PDK1 Invariably Blocks Kras-Driven ADM,
PanIN, and PDAC In Vivo
PI3K activates various downstream effectors by converting
phosphatidylinositol (4,5)-bisphosphate (PIP2) into the second
messenger PIP3. PIP3 transmits PI3K signals by directly binding
to proteins with pleckstrin homology (PH) domains, such as
PDK1 and AKT (Cantley, 2002), targeting them to the cell
membrane. In turn, PDK1 activates AKT by threonine 308 phos-
phorylation (Alessi et al., 1997; Currie et al., 1999).
To test whether cell autonomous signaling of the direct PI3K
downstream target PDK1 is essential for Kras-driven pancreatic
plasticity and PDAC formation, we inactivated Pdk1 specifically
in the epithelial compartment of the pancreas using floxed Pdk1
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Context-Specific Kras Signaling in PDAC and NSCLCmice (Lawlor et al., 2002). Ptf1aCre/+-induced deletion of Pdk1 in
thepancreaswas verifiedbyPCR, quantitativeRT-PCR,Western
blot analysis and immunohistochemistry (Figures S3A–S3C and
S3E–S3G). Consistent with our hypothesis, PDK1 inactivation
completely blocked PanIN and PDAC formation in the KrasG12D
model (Figures 4A–4D). Pancreata showed normal weight and
morphology with some areas of fatty degeneration in older
animals, a common sign of cellular stress due to Kras oncogene
expression (Figures 4B and 4C). Inactivation of PDK1 resulted in
normal life expectancy in the KrasG12D model (Ptf1aCre/+;
LSL-KrasG12D/+;Pdk1f/f), whereas deletion of one Pdk1 allele
(Ptf1aCre/+;LSL-KrasG12D/+;Pdk1f/+) did not alter PanIN and
PDAC formation (Figures 4B, 4D, 4F, and S3G). Loss of epithelial
PDK1 expression in the KrasG12D model correlated well with
PI3K/AKT pathway inactivation (Figures 4E, 4F, and S3I) without
affecting Ras activity (Figure 4G) or PIP3 levels (Figure S3F).
Importantly, we did not observe hypoplasia or developmental
defects of the pancreas, pancreatic islets, and beta cells, or overt
hyperglycemia and lethality due to PDK1 inactivation in pancreas
epithelia as reported by other groups using different Cre-driver
lines and genetic backgrounds (Figures 4B, 4D, S3D, S3G, and
S3H) (Hashimoto et al., 2006; Westmoreland et al., 2009). We
did however observe impaired glucose tolerance, but this did
not progress to diabetes mellitus (Figures S3D and S3H).
Besides AKT, PDK1 also transmits PI3K-dependent signals to
SGK and S6K. The PDK1 effectors RSK and isoforms of PKC are
probably not directly controlled by PI3K (Pearce et al., 2010). To
determine whether PDK1 substrates other than AKT play a role in
KrasG12D-induced pancreatic carcinogenesis, we investigated
whether their phosphorylation states were affected by the
Pdk1 knockout in vivo. Deletion of Pdk1 in the KrasG12D model
blocked PKC, RSK (p90RSK-T359/S363), AKT-T308, and
GSK3b-S9 phosphorylation (Figure S3I). Notably, we observed
considerable variation in the phosphorylation levels of PKC
and RSK in Ptf1aCre/+;LSL-KrasG12D/+ pancreata, whereas AKT
and GSK3b phosphorylation was always uniformly present
(Figure S3I). These results provide biochemical evidence that
canonical AKT-dependent signaling downstream of PI3K/PDK1
contributes significantly to the observed effects, although the
importance of additional PDK1 substrates and alternate effec-
tors cannot be completely excluded (Pearce et al., 2010).
PDK1 Is Essential for Kras-Induced Upregulation
of p16/Ink4 and p19/Arf
To test our hypothesis that PI3K/PDK1 signaling transmits onco-
genic KrasG12D-induced failsafe mechanisms, we investigated
regulation of p16/Ink4 and p19/Arf in pancreata in which the
PI3K signaling pathway had been disrupted (Ptf1aCre/+;LSL-
KrasG12D/+;Pdk1f/f model, Figure 4F). PDK1 deficiency signifi-
cantly reduced p16/Ink4a and p19/Arf induction compared to
Ptf1aCre/+;LSL-KrasG12D/+ animals (Figure 4H). These in vivo
genetic studies therefore support the view that KrasG12D-
dependent oncogenic stress fluxes through PDK1 to induce
upregulation of the p16/Ink4a and p19/Arf tumor suppressors.
Elimination of PDK1 Blocks PDAC, but not NSCLC
Formation
We next evaluated the role of cell autonomous PDK1 signaling
in pancreatic carcinogenesis in PIK3CAH1047R/+ single andPIK3CAH1047R/+;KrasG12D/+ double mutant mice (Figures S4A
and S4B). Deletion of Pdk1 in both models led to complete
inhibition of ADM, PanIN formation, and PDAC development,
indicating that PDK1 is indeed a central node and essential for
pancreatic carcinogenesis in diverse in vivo models (Figures
S4A and S4B).
In contrast, deletion of Pdk1 in KrasG12D-driven NSCLC
models had no effect on lung tumor formation (Figures S4C–
S4F). Although both the KrasG12D-driven lung and pancreatic
cancer models are on a similar genetic background, it remains
possible that subtle differences in the genetic background
may affect KrasG12D signaling and engagement of PDK1. We
therefore used the elastase-1 Cre driver line that recombines
loxP sites in the pancreas and the lung of the same animal
(Figures 5A–5C). Simultaneous KrasG12D expression in both
organs of the same animal induced invasive grade 4 NSCLC
and pancreatic tumorigenesis (Figure 5D). Pdk1 deletion
blocked pancreatic neoplasia completely, whereas NSCLC
formation in the same animal was unaffected (Figures 5E and
5F). Importantly, Pdk1 deletion did not affect overall survival in
this model. All animals in the tumor watch cohort developed
grade 3-4 NSCLC within 600 days (Figure 5F) and the number
of lung lesions was comparable (Figure 5G). These in vivo
findings support the view that each tissue has its own
unique signaling requirement during Kras oncogene-induced
transformation.
Craf Is Dispensable for Kras-Driven PDAC Formation
It has recently been shown that Craf is essential for KrasG12D-
induced NSCLC (Blasco et al., 2011; Karreth et al., 2011). To
investigate the contribution of Craf in pancreatic carcinogenesis,
we inactivated Craf in pancreas epithelium using floxed Craf
mice (Jesenberger et al., 2001). Ptf1aCre/+-induced deletion of
Craf in the KrasG12D-driven PDAC model had no inhibitory effect
on tumor development or progression and did not improve
mouse survival (Figures 6A–6C). Efficient deletion of both Craf
alleles and loss of Craf protein expression was verified by
genotyping PCR, immunohistochemistry and western blot
analysis of PDAC cells isolated from tumor specimens from
Ptf1aCre/+;LSL-KrasG12D/+;Craf1f/f mice (Figures 6D–6F). The
possibility that tumors developed due to incomplete Craf dele-
tion can thus be excluded. Signaling via Craf is therefore
dispensable for initiation of Kras-driven PDAC, supporting the
view that Kras exerts its oncogenic effects in a tissue-specific
manner.
Disruption of PDK1or Inhibition of PI3KSignalingBlocks
Murine and Human ADM In Vitro
To gain insight into the cellular mechanisms of KrasG12D-PI3K-
PDK1-induced transformation, we analyzed early events of
pancreatic carcinogenesis. As shown in Figure 4, deletion of
Pdk1 blocks not only PanIN development, but also ADM in the
KrasG12D model. ADM has recently been suggested to be an
initiating event in human and murine PDAC formation (Aichler
et al., 2012; Caldwell et al., 2012; Morris et al., 2010; Reichert
and Rustgi, 2011). Previous studies demonstrated that trans-
forming growth factor a (TGF-a)/epidermal growth factor
receptor and Ras activation induces ADM in vitro (Means et al.,
2005; Morris et al., 2010; Reichert and Rustgi, 2011).Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc. 411
Figure 4. Epithelial PDK1 Is Essential for KrasG12D-Driven Pancreatic Carcinogenesis
(A) Genetic strategy used to study the cell-autonomous role of the PI3K substrate PDK1 in KrasG12D-driven pancreatic cancer formation.
(B) Representative H&E stains of control (Ptf1aCre/+;LSL-KrasG12D/+) and conditional Pdk1 knockout (Ptf1aCre/+;LSL-KrasG12D/+;Pdk1f/f) mice.
(C) Pancreatic weight of 6-month-old mice with the indicated genotypes (n.s., not significant; **p < 0.01, Student’s t test).
(D) Kaplan-Meier survival analysis of the indicated conditional genotypes. + denotes the wild-type allele, f the conditional allele (n.s., not significant; ***p < 0.001,
log-rank test).
(E) Immunoblot analysis of PI3K/AKT pathway activation in pancreata of 12-month-old Ptf1aCre/+;LSL-KrasG12D/+ and Ptf1aCre/+;LSL-KrasG12D/+;Pdk1f/f
compound mutant mice.
(F) Immunohistochemical analysis of PI3K/AKT pathway activation in the pancreas of 12-month-oldmicewith the indicated genotypes. Arrowheads indicate ADM
and arrows PanIN-1 lesions.
(G) Analysis of activated Ras (Ras-GTP) in the pancreas of 1- and 12-month-old Ptf1aCre/+;LSL-KrasG12D/+ and Ptf1aCre/+;LSL-KrasG12D/+;Pdk1f/f mice.
(H) qRT-PCR analysis of p16/Ink4a and p19/Arf mRNA expression in the pancreas of mice with the indicated genotypes. Data are shown as fold change versus
Ctrl. Insets show representative histology in high magnification. Scale bars, 50 mm for micrographs, 20 mm for insets. Error bars, ± SEM.
See also Figure S3.
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Figure 5. PDK1 Is Essential for KrasG12D-Driven PDAC but not NSCLC Formation
(A) Genetic strategy used to analyze Ela1-CreERTM mediated recombination in the lung and the pancreas of the same animal in the absence of tamoxifen with
a double fluorescent floxed tdTomato-EGFP reporter line (R26mT/mG).
(B and C) Confocal microscopic images of tdTomato (red) and Cre-induced EGFP (green) expression in the lung (B) and pancreas (C) of Ela1-CreERTM;R26mT/mG
(left panel) and CtrlR26mT/mG (right panel) animals. Nuclei were counterstained with TO-PRO-3 (blue). Note the constitutive Cre activity in the pancreas and lung in
the absence of tamoxifen in Ela1-CreERTM animals.
(D) Genetic strategy used to activate KrasG12D in the lung and the pancreas of the same animal (left panel). H&E stained representative microscopic lung sections
graded according to the established 4-stage NSCLC grading system from Ela1-CreERTM;LSL-KrasG12D/+ mouse (upper right panel). Lower right panel:
Representative H&E or alcian blue (AB) stained microscopic pancreas sections from the same animal. Activation of oncogenic KrasG12D in lung and pancreas
using the Ela1-CreERTM driver line induces grade 4 NSCLC and pancreatic neoplasia.
(E) Genetic strategy used to study the role of PDK1 in KrasG12D-driven lung and pancreatic cancer formation in the same animal (left panel). Representative H&E
stainedmicroscopic lung sections graded according to the established 4-stageNSCLC grading system from Ela1-CreERTM;LSL-KrasG12D/+;Pdk1f/fmouse (upper
right panel). Lower right panel: Representative H&E stained microscopic pancreas sections from the same animal. Deletion of Pdk1 blocks ADM and PanIN
formation in the pancreas completely but has no effect on NSCLC development and progression.
(F) Kaplan-Meier survival curves of the indicated genotypes (n.s., not significant; ***p < 0.001, log-rank test). Note: All Ela1-CreERTM;LSL-KrasG12D/+ and
Ela1-CreERTM;LSL-KrasG12D;Pdk1f/f animals developed NSCLC.
(G) Quantification of microscopic lung lesions of Ela1-CreERTM;LSL-KrasG12D/+ and Ela1-CreERTM;LSL-KrasG12D;Pdk1f/f mice (n.s., not significant, Student’s
t test). Insets show representative lesions in high magnification. Scale bars, 50 mm for micrographs, 20 mm for insets. Note: All Ela1-CreERTM animals were
analyzed without Cre activation due to constitutive Cre activity (no tamoxifen treatment). Error bars, ± SEM.
See also Figure S4.
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Figure 6. Craf Is Dispensable for KrasG12D-
Driven Pancreatic Carcinogenesis
(A) Genetic strategy used to study the cell-auton-
omous role of Craf in KrasG12D-driven pancreatic
cancer formation.
(B) Representative H&E stains of control
(Ptf1aCre/+;LSL-KrasG12D/+;Craf f/+) and conditional
Craf knockout (Ptf1aCre/+; LSL-KrasG12D/+;Craf f/f)
mice.
(C) Kaplan-Meier survival analysis of the indicated
conditional genotypes. + denotes the wild-type
allele, f the conditional allele (n.s., not significant;
***p < 0.001, log-rank test).
(D) Genotyping strategy of the floxed Craf allele
(upper panel). PCR analysis of DNA from wild-type
(WT), heterozygous (f/WT) and homozygous (f/f)
conditional floxed Craf mice and Ptf1aCre medi-
ated deletion of exon 3 of Craf (CrafD/D) in
pancreatic cancer cells (PDAC) (lower panel).
Sizes of WT and mutant PCR products are indi-
cated. Note: Efficient recombination of both
floxed Craf alleles in PDAC cells from
Ptf1aCre/+;KrasG12D/+;Craff/f mice.
(E) Immunohistochemical analysis of Craf ex-
pression in PDAC of Ptf1aCre/+;KrasG12D/+;Craff/f
and Ptf1aCre/+;KrasG12D/+;Craf f/+ mice. + denotes
the WT allele, f the conditional allele.
(F) Immunoblot analysis of Craf expression in
primary PDAC cells from mice with the indicated
genotypes. b-actin was used as loading control.
Insets show representative lesions in high magni-
fication. Scale bars, 50 mm for micrographs, 20 mm
for insets.
Cancer Cell
Context-Specific Kras Signaling in PDAC and NSCLCTo test whether TGF-a/Kras-induced ADM formation depends
on intact PDK1 signaling, we isolated acini from Ptf1aCre/+;
KrasG12D/+ and Ptf1aCre/+;KrasG12D/+;Pdk1f/f pancreata and
performed an in vitro ADM assay (Means et al., 2005). Consistent
with the in vivo data (Figures 7A and 7B), we observed that
deletion of Pdk1 completely blocked ADM in the presence
and absence of TGF-a (Figures 7C and 7D). Acini isolated
from Ptf1aCre/+;KrasG12D/+ and Ptf1aCre/+;KrasG12D/+;Pdk1f/f pan-
creata were equally viable (data not shown), thus excluding
differences in cellular vulnerability as a possible cause. ADM
was also blocked by the pan class I PI3K inhibitor GDC 0941,
the PDK1 inhibitor BX912, the dual pan class I PI3K-mTOR
inhibitor NPV-Bez235, and the AKT inhibitor MK-2206
(Figure 7E). Interestingly, the RSK inhibitor BI-D1870 had no
effect on ADM formation even at concentrations as high as414 Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc.10 mM (Figure 7E). These data confirm
our in vivo genetic studies in mice and
indicate that disruption of the canonical
PI3K-PDK1-AKT, but not the PDK1-RSK
axis, blocks ADM and therefore, tumor
initiation in the pancreas.
To test if our murine model system is
relevant to humans, we established
primary acinar cell culture from human
pancreas and performed functional ADM
assays with various PI3K-PDK1-AKT
pathway inhibitors (Figures 7F, 7G, S5A,and S5B). As shown in Figure 7F, TGF-a treatment of human
acinar cells induced ADM, as indicated by CK19 staining, with
concomitant PI3K pathway activation, as evidenced by AKT-
T308 phosphorylation. Treatment with GDC 0941 blocked ADM
significantly in a dose-dependent manner (Figures 7G and
S5A–S5C) and inhibited AKT-T308 phosphorylation and CK19
expression (Figure S5C).
Overall, these data support the notion that PI3K/PDK1
signaling is essential for pancreatic cell plasticity and tumor initi-
ation and important to transmit the oncogenic Kras-induced
program in the pancreas. However, we cannot completely
exclude a role for indirect mechanisms of PI3K activation via
alternate effectors such as receptor tyrosine kinases, rather
than a direct Kras/PI3K interaction (Ardito et al., 2012; Ebi
et al., 2011; Navas et al., 2012).
Figure 7. PI3K Signaling Regulates Human and Murine ADM
(A) Genetic strategy used to study the role of PDK1 in KrasG12D-driven ADM.
(B) Quantification of ADM in 6-month-old Ptf1aCre/+;LSL-KrasG12D/+ and Ptf1aCre/+;LSL-KrasG12D/+;Pdk1f/f mice (n = 3; 3 representative slides per mouse).
(C) Phase contrast images of pancreatic acinar cells with the indicated genotypes 5 days after isolation and treatment with or without TGF-a (50 ng/ml).
(D) Quantification of ductal and acinar structures after 5 days in culture. Bar graph shows percentage of structures of the indicated genotypes with and without
TGF-a treatment.
(E) Quantification of ductal and acinar structures after 5 days in culture with and without treatment with the indicated chemicals. Bar graph shows percentage of
structures of indicated genotype treated with TGF-a and the indicated chemicals.
(F) Confocal microscopic images of TGF-a-induced human ADM. Upper panel: CK19 expression (red) in ADM after 5 days of TGF-a (50 ng/ml) treatment. Lower
panel: CK19 expression (red) and AKT-T308 phosphorylation (green) after 5 days TGF-a treatment. Arrow indicates a cell with acinar morphology but positive
staining for CK19 and pAKT-T308. Nuclei were counterstained with TO-PRO-3 (blue).
(G) Upper panel: Phase contrast images of human pancreatic acinar cells 5 days after isolation and treatment with TGF-a (50 ng/ml) with or without GDC 0941
(1 mM). Lower panel: Quantification of human ductal and acinar structures from two independent patients after 5 days in culture with and without GDC 0941
treatment. Scale bars, 50 mm. Error bars, ± SEM.
See also Figure S5.
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Figure 8. PI3K Signaling Is needed for Human and Murine KrasG12D-Driven Pancreatic Tumor Maintenance
(A) Genetic strategy used to induce Trp53R172H mutant PDAC (KPC mouse model).
(B) KPC mice with mean tumor diameters > 5 mm were enrolled and randomized into the GDC 0941 treatment or control (vehicle) group (n = 3 per group). Tumor
growthwasmonitored by high-resolution ultrasound (Vevo 770System, Visual Sonics). Data represent themean tumor volumes± SD (***p < 0.001, Student’s t test).
(C) Representative high-resolution ultrasound images from KPC mice pre-treatment (left, day 0) and after 14 days on study (right). Visible lesions are outlined in
white and mean tumor burden for each cohort is shown in mm3 in the lower right corner.
(D) Immunoblot analysis of AKT-T308 phosphorylation in primary PDAC specimens from control and GDC 0941 treated KPCmice. a-Tubulin was used as loading
control.
(E) Immunohistochemical BrdU staining of representative PDACs from control and GDC 0941-treated KPC mice indicates blockade of proliferation in the
treatment group. Scale bars, 50 mm.
(F) Quantification of BrdU-positive proliferating cells (three representative slides per mouse; *p < 0.05, Student’s t test). Error bars, ± SEM.
(G) Patient-derived primary PDAC cells (TUM-PaCa1; see Figure S6C) were orthotopically transplanted into the pancreas of NOD-SCID-IL2Rg mice. After
establishment of sizeable tumors, mice were randomized and treated with GDC 0941 or vehicle for 12 days (n = 3 per group). Data represent the mean tumor
volumes ± SD (**p < 0.01, Student’s t test).
See also Figure S6.
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of Murine and Human Pancreatic Cancer
To test whether PI3K-PDK1-AKT signaling could be a
target for pancreatic cancer therapy, we used the well-estab-
lished Ptf1aCre/+;LSL-KrasG12D/+;LSL-Trp53R172H/f (KPC) model
(Figure 8A) (Olive et al., 2009). KPC mice develop primary
PDAC that faithfully recapitulates the molecular, histopatho-416 Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc.logic, and clinical features of the human disease (Olive et al.,
2009).
To inhibit PI3K signaling in vivo, we used GDC 0941, a potent
and selective oral pan class I PI3K inhibitor currently under clin-
ical development (LoRusso et al., 2011; Yuan et al., 2013). GDC
0941 efficiently inhibited the growth of primary murine KrasG12D
and primary human patient-derived PDAC cells in vitro (Figures
Cancer Cell
Context-Specific Kras Signaling in PDAC and NSCLCS6A–S6C). To evaluate the in vivo efficacy of GDC 0941 against
KrasG12D-induced PDAC, KPC mice with established tumors of
comparable size were treated for 14 days with vehicle or GDC
0941 at 150 mg/kg/day. GDC 0941 efficiently blocked tumor
growth as measured by high-resolution ultrasound and reduced
phosphorylation of AKT-T308, a surrogate marker of PI3K
signaling via PDK1 (Figures 8B–8D). All GDC 0941-treated
animals displayed stable disease, whereas vehicle-treated
animals showed rapid disease progression (Figures 8B and
8C). Consistent with this, histopathologic analysis showed
significantly decreased proliferation of GDC 0941-treated
tumors (Figures 8E and 8F).
To demonstrate the relevance of the pathway for human
pancreatic cancer therapy, we used primary patient-derived
PDAC cells transplanted orthotopically into the pancreas of
NOD-SCID-IL2Rg (NSG) mice. We observed very similar anti-
tumor effects of GDC 0941 in this humanized PDAC model
(Figures 8G and S6D). These data strongly suggest that PI3K
signaling is also necessary for proliferation and maintenance of
established murine and human PDAC and that the PI3K-PDK1-
AKT pathway is a promising target for therapeutic interventions.
DISCUSSION
There has been no major breakthrough in the treatment of PDAC
in the past 30 years and no effective targeted therapies are avail-
able (Hidalgo, 2010). Nearly all PDAC harbor KRAS mutations,
but efforts to develop effective Kras inhibitors have generally
failed. It is therefore essential to understand and define the
importance of effectors of mutant Kras and to identify nonredun-
dant essential nodes of nononcogene addiction (Pylayeva-
Gupta et al., 2011). Here, we show that PI3K-PDK1 signaling is
such a node in Kras-driven pancreatic cancer initiation and
maintenance.
It has recently become evident that Craf is essential for the
onset of Kras-driven non-small cell lung cancer (Blasco et al.,
2011; Karreth et al., 2011). However, ablation of Craf in our
KrasG12D-driven PDAC model had no significant inhibitory effect
on tumor development, progression, or survival. This demon-
strates that there are substantial tissue- and context-specific
differences in Kras effector usage. Such differences may have
important clinical implications because they could explain the
diverse response to targeted therapies of different tumor types
harboring oncogenic KRAS mutations. Indeed, a recent study
showed no substantial response of KrasG12D-driven NSCLC
toward PI3K-mTOR inhibition in vivo (Engelman et al., 2008). In
contrast, we demonstrate that targeting the PI3K pathway in
KrasG12D-driven PDAC efficiently blocks carcinogenesis and
tumor progression. Our data thus provide in vivo evidence for
the rationale to investigate Kras-driven oncogenic pathways in
a tissue- and context-specific manner to characterize the rele-
vant nodes engaged in different tumor entities.
Collisson and colleagues found that oncogenic BrafV600E is
capable of inducing PanIN lesions in mice (Collisson et al.,
2012). Using a tamoxifen-inducible transgenic Pdx1-CreERT2-
driver line, they activated a latent BrafV600E allele in the pancreas
of adult mice and observed a greater number of PanIN lesions
than in the classical KrasG12Dmodel. These data and our findings
clearly show that activation or deletion of different Kras-depen-dent signaling pathways can induce or block PanIN formation
in vivo. This argues either for the existence of several distinct
routes toward PanIN formation, or an essential crosstalk between
the Raf-MEK-ERK and PI3K-PDK1-AKT pathway, which might
depend on alternate effectors like receptor tyrosine kinases
(Ardito et al., 2012; Ebi et al., 2011; Navas et al., 2012). Collisson
and colleagues showed that PanIN formation can be caused by
activation of the canonical Raf-MEK-ERK pathway at the level of
Braf.Whether Braf is essential for PanIN formation in theKrasG12D
model, as we show for the direct PI3K downstream target PDK1,
needs to be investigated at the genetic level in the future.
In contrast to our study, Collisson and colleagues found no
PanIN development after tamoxifen induced p110aH1047R
expression in the pancreas using the Pdx1-CreERT2 mouse
line. This might be due to distinct target cells, or differences in
Pik3ca copy number, Cre-induced recombination efficacy, or
different expression and signaling levels of p110a in the Ptf1aCre
and Ela1-CreERTM versus Pdx1-CreERT2 models (Collisson
et al., 2012). Based on the similar phenotypes of our KrasG12D
and PIK3CAH1047R models, the lack of Ras activation in
PIK3CAH1047R mice, comparable levels of PI3K activation and
expression as well as PIP3 levels in the KrasG12D and
PIK3CAH1047R models, and by showing that deletion of the
PI3K effector Pdk1 blocks tumor formation, ADM, and PI3K
activation in theKrasG12Dmodel, we provide evidence atmultiple
levels that Kras acts through PI3K-PDK1 to induce pancreatic
cancer. This conclusion is further supported using primary
human material showing that PI3K signaling is active in human
acinar-to-ductal metaplasia, premalignant pancreatic lesions
and cancers, and is mechanistically involved in early processes
of pancreatic cell plasticity and cancer formation as well as in
tumor maintenance.
Downward and colleagues showed previously that the Ras-
PI3K interaction plays an important role in Ras-induced skin
and lung carcinogenesis (Gupta et al., 2007). They found that
disruption of the direct Ras/p110a interaction—by constitutive
expression of Pik3caT208D/K227A in the mouse germline—dramat-
ically reduced the number of Ras-induced papillomas and lung
adenomas (Gupta et al., 2007). It is however unclear to what
extent this was mediated by cell autonomous or non-cell auton-
omous effects in the host. Since p110a is required for angiogen-
esis (Graupera et al., 2008), disruption of the Ras-PI3K interac-
tion in the vasculature, immune system, or stroma is likely to
contribute significantly to the observed effects in this model.
Because PDK1 is a central node of PI3K signaling (Castellano
and Downward, 2011), we evaluated its cell-autonomous role in
Kras-inducedNSCLC in vivo. Intriguingly, ablation ofPdk1 specif-
ically in the epithelial compartment of the lung using two different
recombination strategies had no significant inhibitory effect on
KrasG12D-induced NSCLC development and progression. This
suggests that PI3K signaling plays an important role in the tumor
microenvironment rather than a cell autonomous function during
NSCLC formation (Graupera et al., 2008). This is supported by the
observation that Ras-induced NSCLC development is impaired
but not completely blocked by constitutive expression of the
Pik3caT208D/K227A in the mouse germline (Gupta et al., 2007). In
contrast to the lung, genetic inactivation of PDK1 in pancreas
epithelium using two different Cre-driver lines completely
blocked KrasG12D-induced neoplastic transformation. TheseCancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc. 417
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cell autonomous signaling requirements during oncogenic trans-
formation. This advance in our understanding of tissue-specific
effects of oncogenic Kras may change clinical practice in the
future because it clearly shows that results cannot simply be
extrapolated from one Kras-driven tumor entity to another.
We have defined the tumor cell autonomous Kras-PI3K-PDK1
axis as an essential pathway of pancreatic cancer with the
capacity to induce cell plasticity, ADM, PanIN, and cancer
formation as well as tumor maintenance. A large variety of phar-
macologic inhibitors directed against the PI3K pathway and the
promising targetable node PDK1 are now available for clinical
investigation (Engelman, 2009; Liu et al., 2009; Pearce et al.,
2010). Recognition of the importance of the PI3K-PDK1 pathway
in PDAC, as demonstrated in this study, will provide a more
effective approach for targeted therapeutic interventions for
this grave disease.
EXPERIMENTAL PROCEDURES
Mouse Strains and Tumor Models
LSL-KrasG12D/+ (Hingorani et al., 2003), Ptf1aCre/+ (Eser et al., 2011; Nakhai
et al., 2007; Seidler et al., 2008), LSL-Rac1G12V/+ (Srinivasan et al., 2009),
LSL-Trp53R172H/+ (Hingorani et al., 2005), Trp53f/+ (Jonkers et al., 2001),
LSL-R26lacZ/+ (Seidler et al., 2008), R26mT/mG (Muzumdar et al., 2007),
Ela1-CreERTM (Stanger et al., 2005), Cdkn2af/+ (Aguirre et al., 2003), Craff/+
(Jesenberger et al., 2001), and Pdk1f/+ (Lawlor et al., 2002) mice have been
described previously. The strains were interbred to obtain mice with activation
of distinct pathways in the pancreas as previously described (Eser et al., 2011).
All animal studies were conducted in compliance with European guidelines
for the care and use of laboratory animals and were approved by the Institu-
tional Animal Care and Use Committees (IACUC) of Technische Universita¨t
Mu¨nchen, Regierung von Oberbayern and UK Home Office.
Human Pancreatic Tissue Samples
This study conformed to the Declaration of Helsinki and was approved by the
ethics committee of the Technische Universita¨t Mu¨nchen. Informed consent
was obtained from all patients included in the study.
Generation of Primary Human andMurine Ductal Pancreatic Cancer
Cell Lines
Primary dispersed murine pancreatic cancer cells were established from
Ptf1aCre/+;LSL-KrasG12D/+ and Ptf1aCre/+;LSL-PIK3CAH1047R/+ mice and culti-
vated as previously described (von Burstin et al., 2009). Primary dispersed
human PDAC cells were isolated from surgically resected human PDAC as
recently described (Conradt et al., 2011). Only early-passage (passage 3 to
4) dispersed cells were used for assays.
Establishment of Patient-Derived Xenograft Tumors from Primary
Human PDAC
Tissueswere placed into chilled sterile RPMI 1640 (Thermo Scientific/Hyclone,
Waltham, MA) supplemented with 1% (v/v) penicillin/streptomycin/amphoter-
icin B. The tumor was washed twice, dissected into 3 mm cubes and pieces
were implanted subcutaneously into NOD SCIG IL2Rg (NSG) mice (#005557;
Jackson Laboratory, Bar Harbor, Maine) within 1 hour of resection.
Patient-Derived Orthotopic Human Pancreatic Cancer
Xenotransplantation Model
One million patient-derived primary human pancreatic cancer cells in 20 ml Dul-
becco’smodifiedEaglemediumwere implantedorthotopically into the pancreas
of NSG mice as described (von Burstin et al., 2009; von Burstin et al., 2008).
Statistical Analyses
Comparisons between data setsweremadewith analysis of variance, followed
by Students t test. A Bonferroni correction of the p values was performed for418 Cancer Cell 23, 406–420, March 18, 2013 ª2013 Elsevier Inc.multiple testing. Kaplan-Meier survival curves were compared by log-rank
test. Values of p < 0.05 or less were considered to be statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.01.023.
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